Item 1.01 Entry into a Material Definitive Agreement.

Exit ABL Credit Agreement

On the Effective Date, pursuant to the Plan, QHC and Quincy Health and certain subsidiaries of QHC have entered into that certain Credit and Guaranty Agreement, dated July 7, 2020 (the "Exit ABL Credit Agreement"), among QHC, as a borrower ( "ABL Borrower" and, together with any other person that becomes a party to the Exit ABL Credit Agreement as a borrower, the "ABL Borrowers"), Quincy Health, certain subsidiaries of QHC as guarantors (the "ABL Subsidiary Guarantors" and, together with Quincy Health, the "ABL Guarantors"), Credit Suisse AG, New York Branch, as administrative agent (the "ABL Agent"), and the lenders party thereto.

The Exit ABL Credit Agreement provides for an asset-based revolving loan facility in the maximum principal amount of $145 million (the "Exit ABL Facility"), subject to a borrowing base. Under the borrowing base provisions, the ABL Borrowers are only permitted to draw revolving loans in an amount equal to (i) 85% of the aggregate amount of the ABL Borrowers' and ABL Subsidiary Guarantors' domestic eligible accounts receivable, plus (ii) 50% of the aggregate amount of the ABL Borrowers' and ABL Guarantors' supplemental program eligible accounts receivable, minus (iii) the sum of any reserves established by the ABL Agent in its permitted discretion. Further, at least $21 million of the Exit ABL Facility is available for the issuance of letters of credit to the ABL Borrowers. The ABL Borrowers must use the proceeds of the Exit ABL Facility to, among other things, refinance the existing $125 million senior secured asset-based credit facility (the "ABL Facility") of QHC provided for under that certain ABL Credit Agreement, dated April 29, 2016, among the Company, the lenders party thereto and UBS AG, Stamford Branch, as administrative agent and collateral agent (the "ABL Credit Agreement"). After the refinancing of the ABL Facility, the ABL Borrowers may use the proceeds of the Exit ABL Facility for working capital, capital expenditures and other general corporate purposes.

The Exit ABL Facility bears interest at a rate per annum equal to the sum of (i) the London interbank offering rate ("LIBOR") (with a floor of 1.00%), and (ii) a margin of 3.75%. The ABL Borrowers also paid an arranger fee equal to 1.25% of the aggregate principal amount of the Exit ABL Facility on the Effective Date. In addition to the upfront arranger fee, the ABL Borrowers must pay an unused facility fee equal to 0.5% per annum of the unborrowed principal available to the ABL Borrowers under the Exit ABL Facility. Upon the occurrence . . .

Item 1.02 Termination of a Material Definitive Agreement.

Equity Interests

On the Effective Date, by operation of the Plan, all agreements, instruments, and other documents evidencing, relating to or connected with any equity interests of QHC, including the existing common stock, restricted stock, and restricted stock units issued and outstanding immediately prior to the Effective Date, and any rights of any holder in respect thereof, were deemed cancelled, discharged and of no force or effect.

Employment Agreements and Change in Control Severance Agreements

In connection with the Company's emergence from the Chapter 11 Cases, the Company intends to reject the employment agreements and change in control severance agreements that QHC had previously entered into with certain of its executive officers and other senior management, and such agreements will be cancelled and terminated. Quincy Health is currently in the process of negotiating new employment arrangements and/or other severance agreements with its executive officers and other senior management.

DIP Credit Agreement

On the Effective Date, the Superpriority Secured Debtor-in-Possession Credit Agreement, dated as of April 10, 2020, by and among QHC, as the borrower, certain subsidiaries of QHC party thereto as guarantors, the lenders party thereto, GLAS USA LLC, as administrative agent for the lenders, and GLAS Americas, LLC, as collateral agent for the lenders (the "DIP Credit Agreement"), with respect to that certain $100 million debtor-in-possession facility (the "DIP Facility"), was paid in full and terminated.

Senior Notes and Credit Agreements

On the Effective Date, by operation of the Plan, all outstanding obligations under each of the following debt instruments were cancelled and the applicable agreements governing such obligations were terminated:





         •   Term Loan Agreement with respect to the Term Loan Facility and
             Revolving Credit Facility;




  •   ABL Credit Agreement with respect to the ABL Facility; and




         •   $400 million in aggregate principal amount of 11.625% Senior Notes due
             2023 (the "Senior Notes") issued by QHC pursuant to that certain
             Indenture, dated as of April 22, 2016, by and between QHC and
             Wilmington Savings Fund Society, FSB, as successor trustee to Regions
             Bank.

--------------------------------------------------------------------------------

Item 1.03 Bankruptcy or Receivership.

As disclosed above, on June 30, 2020, the Bankruptcy Court entered the Confirmation Order, which approved the Disclosure Statement and confirmed the Plan.

Summary of Material Features of the Plan

The following is a summary of the material terms of the Plan. This summary highlights only certain substantive provisions of the Plan and is not intended to be a complete description of the Plan. This summary is qualified in its entirety by reference to the full text of the Confirmation Order and the Plan, which are attached hereto as Exhibits 99.1 and 2.1 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

Treatment of Claims and Interest under the Plan

As discussed in further detail in the Plan, the Plan provides for, among other things, the following treatment of claims against and interests in the Company:





         •   each holder of a claim arising under (i) the DIP Facility advanced to
             the Company or (ii) the DIP Claims will be paid in full in cash on the
             Effective Date;




         •   any reasonable and documented expenses incurred by the DIP Agent in
             connection with the DIP Facility will be paid in full in cash on the
             Effective Date;




         •   the DIP Facility, the DIP Credit Agreement, and all related loan
             documents will be deemed cancelled and all liens arising under the DIP
             Facility will automatically terminate;




         •   each holder of an administrative expense, priority tax, or other
             priority claim will receive payment in full in cash;




         •   each holder of a claim arising under the ABL Credit Facility will be
             paid in full in cash on the Effective Date from the proceeds of the
             Exit ABL Facility;




         •   each holder of a claim arising under the Term Loan Facility will
             receive its pro rata share of: (i) $50 million in cash, and (ii) the
             Exit Facility;




         •   each holder of a claim arising under the Revolving Credit Facility
             will receive its pro rata share of (i) cash in the amount of (A) the
             aggregate principal amount outstanding of the Revolving Credit
             Facility, multiplied by (B) a ratio equal to (x) the cash paid to
             holders of claims arising under the Term Loan Facility divided by
             (y) the aggregate principal amount outstanding under the Term Loan
             Facility; and (ii) the Exit Facility;
. . .

Item 2.03 Creation of Direct Financial Obligation or an Obligation under an

Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 regarding the Exit ABL Facility, Exit Facility, Exit ABL Credit Agreement, and Exit Term Loan Agreement is incorporated by reference into this Item 2.03.

Item 3.02 Unregistered Sales of Equity Securities.

On the Effective Date, pursuant to the Plan, Quincy Health issued 28,166,674 Class A Units (including approximately 1.5 million Class A Units in respect of an equity commitment premium) for an aggregate purchase price equal to $200,000,000.03 pursuant to the terms and conditions set forth in the Equity Commitment Agreement. Such Class A Units were issued in reliance upon the exemptions from the registration requirements of the Securities Act provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.

In addition, on the Effective Date, pursuant to the Plan, 3,913,818 Class A Units of Quincy Health became issuable to the former holders of the Senior Notes pursuant to the Plan, of which 3,152,062 Class A Units have been issued as of the Effective Date. Such Class A Units have been or will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Section 1145 of the Bankruptcy Code.

--------------------------------------------------------------------------------

Item 3.03 Material Modification to the Rights of Security Holders.

The information set forth under the Introductory Note and Items 1.01, 1.02, 1.03, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.01 Changes in Control of Registrant.

On the Effective Date, pursuant to the Plan, QHC became a wholly owned subsidiary of Quincy Health, and all of the shares of common stock of QHC, together with any shares of restricted stock, restricted stock units, or any other right to receive equity in QHC, in each case, outstanding immediately prior to the Effective Date, were cancelled, discharged, and of no force and effect. On the Effective Date, pursuant to the Plan, Quincy Health issued Class A Units to holders of the Company's Senior Notes and Equity Commitment Agreement.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

Appointment of Managers and Officers of Quincy Health

As the ultimate parent of QHC, Quincy Health will control the business and affairs of QHC after the Effective Date. Quincy Health is managed and controlled by a board of managers comprised of Murtaza Ali, Joey A. Jacobs, Catherine M. Klema, Michael Rothbart, Alice D. Schroeder, Andrew E. Schultz, and Dan Slipkovich. The executive officers of Quincy Health are the same as QHC's executive officers prior to the Effective Date, except that Joey A. Jacobs will serve as President and Chief Executive Officer of Quincy Health.

Departure of Directors of QHC

On the Effective Date, pursuant to the Plan, Robert H. Fish, Joseph A. Hastings, D.M.D., Jon H. Kaplan, Barbara R. Paul, M.D., Terry Allison Rappuhn, William P. Rutledge, Alice D. Schroeder, and R. Lawrence Van Horn, Ph.D. resigned from the QHC Board.

Appointment of Directors of QHC

On the Effective Date, Quincy Health appointed Alfred Lumsdaine, R. Harold McCard, Jr., and Martin D. Smith to the QHC Board. These individuals also serve as the directors of a majority of QHC's direct and indirect subsidiaries. There are no arrangements or understandings between Messrs. Lumsdaine, McCard, and Smith and any other person pursuant to which Messrs. Lumsdaine, McCard, and Smith were selected as directors. QHC is not aware of any transaction in which Messrs. Lumsdaine, McCard, or Smith have an interest requiring disclosure under Item 404(a) of Regulation S-K.

Departure of Officer of QHC

As of the Effective Date, Robert H. Fish resigned as President and Chief Executive Officer of QHC and as an officer and director of any of QHC's subsidiaries.

In connection with his resignation, on the Effective Date, QHC entered into a Separation Letter Agreement (the "Separation Agreement") with Mr. Fish. The Separation Agreement, effective on the Effective Date, ended Mr. Fish's employment with QHC and provided, among other things, that, in exchange for Mr. Fish's release of all claims arising out of or relating to Mr. Fish's employment with QHC and his resignation therefrom, within thirty (30) days of the Effective Date, Mr. Fish would receive: (i) (a) Mr. Fish's annual base salary through the Effective Date, (b) reasonable documented unreimbursed business expenses, (c) accrued vacation pay and (d) unpaid car allowance, housing allowance or relocation expenses, (ii) any vested benefits or vested equity benefits granted in accordance with the terms of the applicable plan or agreement and (iii) $2.85 Million payable on the Effective Date. The restrictive covenants set forth in Mr. Fish's employment agreement shall continue and remain in effect in accordance with the terms thereof.

The foregoing is only a summary of the Separation Agreement with Mr. Fish and does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached hereto as Exhibit 10.3 and is incorporated herein by reference.

--------------------------------------------------------------------------------

Appointment of Officers of QHC

As of the Effective Date, Alfred Lumsdaine, 55, was appointed as President of QHC, Martin D. Smith, 53, was appointed as Executive Vice President of QHC, Lee C. Fleck, 48, was appointed as Vice President of Finance and Treasurer of QHC, and R. Harold McCard, Jr., 59, was appointed as SVP and Secretary of QHC. These individuals also serve as the officers of a majority of QHC's direct and indirect subsidiaries. There are no arrangements or understandings between Messrs. Lumsdaine, Smith, Fleck and McCard and any other person pursuant to which Messrs. Lumsdaine, Smith, Fleck and McCard were selected as officers. There are no family relationships between Messrs. Lumsdaine, Smith, Fleck and McCard and any director or other executive officer of QHC. QHC is not aware of any transaction in which Messrs. Lumsdaine, Smith, Fleck or McCard have an interest requiring disclosure under Item 404(a) of Regulation S-K. The principal occupation and employment experience of Messrs. Lumsdaine, Smith, and McCard during the last five years is set forth in QHC's Annual Report on Form 10-K for the year ended December 31, 2019, as filed with SEC on April 10, 2020, and is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

Year.

On the Effective Date, in connection with QHC's implementation of the Plan, the Amended Certificate and Amended By-Laws were adopted and approved, and the Amended Certificate was filed with the Delaware Secretary of State. The Amended Certificate and Amended By-Laws contain provisions that are customary for governance documents of wholly-owned subsidiaries of privately-held companies. Copies of the Amended Certificate and Amended By-Laws are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

Suspension of SEC Reporting Obligations

QHC intends to file post-effective amendments to each of its Registration Statements on Form S-8 and a Form 15 with the SEC on July 7, 2020 to suspend its reporting obligations under Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Upon filing the Form 15, QHC's obligations to file certain reports and forms with the SEC, including Forms 10-K, 10-Q and 8-K, will be immediately suspended.

Press Release

On July 7, 2020, the Company issued a press release announcing the Effective Date of the Plan and the Company's emergence from the Chapter 11 Cases. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Cleansing Material

The Company is a party to certain confidentiality agreements (collectively, the "NDAs") entered into with certain creditors (the "Consenting Stakeholders") party to that certain Restructuring Support Agreement, dated April 6, 2020. Pursuant to the NDAs, the Company agreed to publicly disclose certain information, including material non-public information disclosed to the Consenting Stakeholders (the "Cleansing Material") upon the occurrence of certain events set forth in the NDAs. A copy of the Cleansing Material, including descriptions of the sources and uses of the transactions undertaken pursuant to the Plan on the Effective Date, the capitalization of QHC and Quorum Health after the Effective Date and information on cash flows and other operations and financial performance, along with accompanying supplemental materials, is attached hereto as Exhibit 99.3 and is incorporated into this Item 7.01 by reference.

The descriptions in this Form 8-K of the Cleansing Material do not purport to be complete and are qualified in their entirety by reference to the complete presentation of the Cleansing Material attached as Exhibit 99.3 hereto.

The information set forth in Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Form 8-K shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless of any incorporation by reference language in any such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements, other than statements of historical facts, included in this filing that address activities, events or developments that the Company expects, believes, targets or anticipates will or may

--------------------------------------------------------------------------------

occur in the future are forward-looking statements. The Company's actual results may differ materially from those anticipated in these forward-looking statements as a result of certain risks and other factors, which could include the following: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the Company's ability to implement the Plan effectively; the effects of the Chapter 11 Cases on the Company and on the interests of various constituents; the length of time the Company will continue to operate under the supervision of the Bankruptcy Court; the potential adverse effects of the Chapter 11 Cases on the Company's liquidity or results of operations and increased legal and other professional costs necessary to execute the Company's financial restructuring; and the effects and the length of the 2019 novel coronavirus (COVID-19)pandemic as well as other risk factors set forth in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K (including any amendments to those reports) filed with the SEC. The Company therefore cautions readers against relying on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on the Company's behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and, except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.






  (d) Exhibits




No.     Description

2.1       Debtors' Joint Prepackaged Chapter 11 Plan of Reorganization, dated as
        of April 7, 2020, as amended or supplemented on April 27, 2020, June 5,
        2020, June 12, 2020, and June  30, 2020

3.1       Second Amended and Restated Certificate of Incorporation of QHC

3.2       Second Amended and Restated By-Laws of QHC

10.1      Credit Agreement and Guaranty, dated July 7, 2020, among the ABL
        Borrowers, the ABL Guarantors, the ABL Agent, as a lender and the
        collateral agent, and the lenders party thereto

10.2      Credit Agreement, dated July 7, 2020, among the Term Loan Borrower, the
        Term Loan Guarantors, the Term Loan Agent, and the lenders party thereto


10.3      Separation Letter Agreement, dated July 7, 2020, by and between QHC and
        Robert H. Fish

99.1      Findings of Fact, Conclusions of Law, and Order Approving the Debtors'
        Disclosure Statement for, and Confirming, the Debtors' Joint Prepackaged
        Chapter 11 Plan of Reorganization, dated June  30, 2020

99.2      Press Release

99.3      Cleansing Material

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses